ArticleJournal of chemotherapy (Florence, Italy)2014
Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel.
Article in Journal of chemotherapy (Florence, Italy), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.The Journal of antimicrobial chemotherapy · 2019Trial
- A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.The Journal of antimicrobial chemotherapy · 2016Trial
- Rationale and Logistics of Continuous Infusion Cephalosporin Antibiotics.Pharmacy (Basel, Switzerland) · 2024Review
- The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.CPT: pharmacometrics & systems pharmacology · 2021Article
- Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.The Journal of antimicrobial chemotherapy · 2019Article
- Review
- In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.Antimicrobial agents and chemotherapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activity of ceftaroline was tested against 8233 isolates mainly collected from bloodstream, urinary, respiratory and skin and soft tissue specimens in European medical centers during 2011. This cephalosporin displayed activity against Staphylococcus aureus (MIC(50), 0·25 mg/l), with greater activity against MRSA (MIC(50), 1 mg/l) than other β-lactams tested. Against Streptococcus pneumoniae, including penicillin-resistant strains, other streptococcal groups and Haemophilus spp., ceftaroline was highly active and MIC90 values ranged from ≤0·015 to 0·12 mg/l. Ceftaroline, like other cephalosporins, had limited activity against ESBL-phenotype Enterobacteriaceae, but showed good activity against isolates not displaying an ESBL-phenotype. Ceftaroline remains very active against MRSA and other organisms than could be associated with its approved indications in the EU (complicated skin and soft tissue infections and community-acquired pneumonia).
Indexed as
Identifiers
24070006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.